A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

driven by monoclonal antibodies like Aducanumab and Leqembi, which offer potential disease-modifying effects for advanced Alzheimer's stages. Alzheimer's Drugs Market Analysis by Distribution ...

Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...

An update to our reporting on two recently-approved Alzheimer’s drugs: aducanumab and Lecanemab. FDA advisers and many independent watchdogs said there's no good evidence the hugely expensive shots ...